EGFR and non-small cell lung carcinoma: The phase 1/1B trial, CHRYSALIS, evaluated amivantamab as monotherapy, in combination with lazertinib (a brain-penetrant third generation EGFR TKI), or with carboplatin plus pemetrexed in post-osimertinib and post-platinum EGFRm NSCLC [68].